Postencephalitic Parkinsonism

Tablets Used as an anticholinergic CNS depressant in the symptomatic treatment of postencephalitic parkinsonism and paralysis agitans in spastic states and locally as a substitute for atropine in ophthalmology.

Postencephalitic parkinsonism 2 mg/day in 1 dose or more. In highly sensitive patients, begin therapy with 0.5 mg at bedtime increase as necessary. 

Treatment of symptoms of idiopathic Parkinson s disease (paralysis agitans), postencephalitic parkinsonism, and sympathetic parkinsonism that may follow injury to the nervous system by carbon monoxide and manganese intoxication. 

Parkinson s disease Treatment of idiopathic or postencephalitic Parkinson s disease. 

Other progressive neurologic disorders that affect components of frontal-subcortical circuits (e.g., postencephalitic Parkinson s disease, neuroacanthocytosis, progressive supranuclear palsy, and Huntington s disease) also can present with OCD symptoms (Cum-... 

It was Louis Lewin, of Phantastica fame, who first suggested that banister-ine might be useful in the treatment of diseases of the nervous system. And it was Kurt Beringer, of der Meskalinrausch fame, who ran the first clinical study using banisterine on 15 patients with postencephalitic parkinsonism, in 1928. Other studies reinforced the virtues of this drug. Initially, doses of 20 or 40 mg were... 

Casals J, Elizan TS, Yahr MD (1998) Postencephalitic parkinsonism—a review. J Neural Transm 105 645-676. 

Idiopathic parkinsonism PO/IM initially 0.5-1 mg/day at bedtime up to 6 mg/day Postencephalitic parkinsonism PO/IM 2 mg/day as single or divided dose Drug-induced extrapyramidal symptoms PO/IM 1 1 mg one to two times/day Acute dystonic reactions IM/TV 1-2 mg, then 1-2 mg PO two times/day to prevent recurrence... 

---